News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
620,256 Results
Type
Article (47687)
Company Profile (221)
Press Release (572348)
Section
Business (177181)
Career Advice (2584)
Deals (32630)
Drug Delivery (122)
Drug Development (78979)
Employer Resources (161)
FDA (16281)
Job Trends (13633)
News (313731)
Policy (32474)
Tag
Academia (2412)
Alliances (44784)
Alzheimer's disease (1391)
Approvals (16234)
Artificial intelligence (212)
Bankruptcy (324)
Best Places to Work (10195)
Breast cancer (225)
Cancer (1714)
Cardiovascular disease (136)
Career advice (2150)
CAR-T (125)
Cell therapy (365)
Clinical research (63682)
Collaboration (640)
Compensation (377)
COVID-19 (2646)
C-suite (160)
Data (1575)
Diabetes (218)
Diagnostics (5585)
Earnings (69372)
Employer resources (146)
Events (93793)
Executive appointments (554)
FDA (17190)
Funding (547)
Gene therapy (262)
GLP-1 (747)
Government (3997)
Healthcare (15997)
Infectious disease (2765)
Inflammatory bowel disease (124)
Interviews (473)
IPO (15325)
Job creations (3860)
Job search strategy (1806)
Layoffs (493)
Legal (7860)
Lung cancer (256)
Manufacturing (250)
Medical device (11491)
Medtech (11495)
Mergers & acquisitions (17680)
Metabolic disorders (616)
Neuroscience (1826)
NextGen: Class of 2025 (5527)
Non-profit (3430)
Northern California (2011)
Obesity (353)
Opinion (246)
Patents (165)
People (52050)
Phase I (19614)
Phase II (27677)
Phase III (21552)
Pipeline (730)
Postmarket research (2609)
Preclinical (7936)
Radiopharmaceuticals (238)
Rare diseases (342)
Real estate (5399)
Regulatory (22442)
Research institute (2225)
Resumes & cover letters (426)
Southern California (1697)
Startups (3328)
United States (17482)
Vaccines (696)
Weight loss (269)
Date
Last 7 days (607)
Last 30 days (2443)
Last 365 days (33271)
2025 (4420)
2024 (33904)
2023 (37956)
2022 (48577)
2021 (52358)
2020 (49729)
2019 (40560)
2018 (30960)
2017 (31274)
2016 (30064)
2015 (33729)
2014 (27400)
2013 (23041)
2012 (24703)
2011 (25297)
2010 (23250)
Location
Africa (783)
Arizona (172)
Asia (38655)
Australia (6229)
California (4522)
Canada (1505)
China (375)
Colorado (211)
Connecticut (239)
Europe (87230)
Florida (666)
Georgia (145)
Illinois (411)
Indiana (226)
Japan (121)
Maryland (733)
Massachusetts (3511)
Michigan (167)
Minnesota (297)
New Jersey (1309)
New York (1270)
North Carolina (831)
Northern California (2011)
Ohio (149)
Pennsylvania (1010)
South America (1160)
Southern California (1697)
Texas (651)
Utah (124)
Washington State (449)
620,256 Results for "galderma pharma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 14, 2025
·
13 min read
Press Releases
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 18, 2025
·
7 min read
Press Releases
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
December 13, 2024
·
14 min read
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
November 28, 2024
·
10 min read
Press Releases
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
December 16, 2024
·
14 min read
FDA
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 9, 2024
·
4 min read
Press Releases
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
October 21, 2024
·
9 min read
Immunology and inflammation
Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis
The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.
August 13, 2024
·
2 min read
·
Tristan Manalac
NextGen
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.
February 18, 2025
·
2 min read
·
Annalee Armstrong
1 of 62,026
Next
